Veterans saw dramatic PTSD improvements in trials, but the government's rush to approve ibogaine specifically worries experts.
A Stanford study of 30 combat veterans with PTSD found that ibogaine therapy reduced symptoms by 88% within a month. Depression dropped 87% and anxiety fell 81%. Veterans' disability ratings went from severe (30+) to essentially none (5.1). These numbers are remarkable for any mental health treatment, but they come from a single small study of a drug that has killed people.
The government is fast-tracking ibogaine despite having much more safety data on psilocybin and MDMA. Ibogaine affects heart rhythm in ways that can cause cardiac arrest — it's probably the most dangerous psychedelic compound being studied. Meanwhile, psilocybin and MDMA have already earned breakthrough therapy status from the FDA and have larger, more robust trial data.
This matters because veterans deserve treatments that work without unnecessary risk. The mental health crisis among veterans is real and urgent, but rushing a potentially dangerous drug to market when safer alternatives exist seems backwards. The most effective PTSD treatments combine medication with proven therapies, not just a single compound.
What You Can Actually Do Today
- Ask your doctor about FDA-approved PTSD treatments like prolonged exposure therapy or EMDR if you're struggling with symptoms
- Follow clinical trial registries if you're interested in legal psychedelic therapy options — psilocybin trials are more widely available
- Avoid underground ibogaine clinics in Mexico or elsewhere — the cardiac risks are real and medical oversight varies widely
Psychedelic therapies are experimental. Never stop prescribed medications or seek underground treatments without medical supervision.
